Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

(GLSI), a clinical-stage biopharmaceutical company, on Monday announced a preliminary update from its open-label analysis of HLA data in the ongoing Phase III FLAMINGO-01 clinical trial.

(Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

(NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data from the Phase III FLAMINGO-01 clinical trial.